Nexus Surgical and Medicare Ltd Upgraded to Hold on Technical and Financial Improvements

Technical Trends Signal Renewed Momentum

The primary catalyst for the upgrade stems from a marked improvement in the technical grade, which shifted from mildly bullish to bullish. Key technical indicators underpinning this shift include a bullish stance in Bollinger Bands on both weekly and monthly charts, alongside a daily moving average that supports upward momentum. The KST (Know Sure Thing) indicator presents a bullish weekly signal, although it remains mildly bearish on the monthly timeframe, suggesting some caution in the longer term.

Meanwhile, the MACD (Moving Average Convergence Divergence) remains mildly bearish on a weekly basis but bullish monthly, indicating mixed but improving momentum. The Relative Strength Index (RSI) currently shows no significant signals on either weekly or monthly charts, while Dow Theory trends remain neutral. Overall, the technical picture has brightened considerably, with the stock price rising 6.87% on the day to ₹21.00 from a previous close of ₹19.65, nearing its 52-week high of ₹25.50.

Financial Trend: Positive Quarterly Performance and Consistent Returns

Financially, Nexus Surgical has demonstrated robust performance in the latest quarter (Q4 FY25-26), with net sales for the nine months ending March 2026 rising to ₹6.15 crores and profit after tax (PAT) increasing to ₹0.58 crores. The company also reported its highest quarterly PBDIT at ₹0.30 crores, underscoring operational efficiency improvements.

Long-term financial strength is evident in the company’s average Return on Equity (ROE) of 31.15%, with the most recent figure at an impressive 40.6%. This strong profitability metric supports the company’s fundamental quality and underpins investor confidence. Nexus Surgical has consistently outperformed the BSE500 index over the past three years, generating an 18.64% return in the last year alone compared to the index’s negative 8.72% return. Over five years, the stock has delivered a staggering 600% return, vastly outpacing the Sensex’s 46.01% gain.

Valuation: Expensive Yet Discounted Relative to Peers

Despite strong financials, Nexus Surgical’s valuation remains on the expensive side, with a Price to Book (P/B) ratio of 6.4, reflecting a premium over book value. This elevated valuation is supported by the company’s high ROE of 40.6%, which often justifies premium pricing. However, when compared to its peer group’s historical valuations, the stock is trading at a relative discount, suggesting some room for appreciation.

The company’s Price/Earnings to Growth (PEG) ratio stands at a low 0.3, indicating that earnings growth is not fully priced in by the market. Over the past year, profits have risen by 23%, outpacing the stock’s 18.64% return, which further supports the argument for a valuation upgrade. Investors should note, however, that the micro-cap status and relatively high valuation require careful monitoring for potential volatility.

Quality Assessment: Strong Fundamentals and Shareholder Structure

Nexus Surgical’s quality grade has improved, reflecting its strong fundamentals and consistent profitability. The company’s average ROE of 31.15% over recent years is a testament to efficient capital utilisation and sound management. The majority of shareholders are non-institutional, which can sometimes imply higher volatility but also indicates strong retail investor interest.

The company’s financial discipline and positive quarterly results reinforce its quality credentials. While the Mojo Score remains at 50.0 with a Hold grade, this is a significant improvement from the previous Sell rating, signalling a more balanced risk-reward profile for investors.

Stock Performance Relative to Market Benchmarks

Examining returns relative to the Sensex highlights Nexus Surgical’s outperformance over multiple time horizons. The stock has delivered a 20.00% year-to-date return compared to the Sensex’s negative 9.96%, and a 3-year return of 112.98% versus the Sensex’s 20.05%. However, the 10-year return is negative at -57.96%, contrasting with the Sensex’s strong 186.94% gain, reflecting past challenges that the company appears to have overcome in recent years.

Shorter-term returns show some volatility, with a 1-week decline of 3.63% against a minor Sensex dip of 0.47%, but a 1-month gain of 5.53% outpacing the Sensex’s 2.61%. This mixed performance underscores the importance of the recent technical upgrade as a potential signal for renewed momentum.

Outlook and Investor Considerations

The upgrade to a Hold rating reflects a more balanced view of Nexus Surgical’s prospects. The technical indicators suggest a bullish trend gaining traction, while financial results demonstrate improving profitability and operational strength. Valuation remains elevated but is tempered by strong growth metrics and a low PEG ratio, indicating potential undervaluation relative to earnings growth.

Investors should weigh the company’s micro-cap status and the inherent volatility associated with non-institutional shareholder dominance. However, the consistent returns over the last three years and the company’s ability to outperform broader indices provide a compelling case for cautious optimism.

In summary, Nexus Surgical and Medicare Ltd’s upgrade to Hold is underpinned by a confluence of improved technical signals, solid financial trends, strong quality fundamentals, and a valuation that, while expensive, offers relative value compared to peers. This nuanced assessment suggests that the stock is positioned for potential gains, albeit with a need for ongoing monitoring of market and company-specific developments.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →